公开(公告)号：US11034700B2

公开(公告)日：2021-06-15

申请号：US16491794

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Satoshi Mikami ,  Masaki Daini ,  Yuhei Miyanohana ,  Hideo Suzuki ,  Kenichiro Shimokawa ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: A61K31/40 ,  C07D491/107 ,  C07D207/12 ,  C07D207/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D403/12 ,  C07D405/06 ,  C07D405/10 ,  C07D409/06 ,  C07D409/12 ,  C07D413/10 ,  C07D413/12

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US09920047B2

公开(公告)日：2018-03-20

申请号：US15270863

申请日：2016-09-20

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shigemitsu Matsumoto ,  Yasushi Hattori ,  Masashi Toyofuku ,  Shinji Morimoto ,  Masaki Daini ,  Takuto Kojima ,  Tomohiro Kaku ,  Mitsuhiro Ito

IPC: C07D417/14 ,  C07D417/12 ,  C07D409/12 ,  C07D307/79 ,  C07D407/12 ,  C07D213/82 ,  C07D333/38 ,  C07D413/14 ,  C07D231/14 ,  C07D333/40 ,  C07D285/135 ,  C07D231/12 ,  C07D277/56 ,  C07D409/14 ,  C07D413/12 ,  C07D307/81 ,  C07D285/08

CPC classification number: C07D417/14 ,  C07D213/82 ,  C07D231/12 ,  C07D231/14 ,  C07D277/56 ,  C07D285/08 ,  C07D285/135 ,  C07D307/79 ,  C07D307/81 ,  C07D333/38 ,  C07D333/40 ,  C07D407/12 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

公开(公告)号：US20150141406A1

公开(公告)日：2015-05-21

申请号：US14404126

申请日：2013-05-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi Nara ,  Masaki Daini ,  Akira Kaieda ,  Taku Kamei ,  Toshihiro Imaeda ,  Fumiaki Kikuchi

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有优异的JAK抑制作用的化合物，其可用作预防或治疗自身免疫性疾病（类风湿性关节炎，牛皮癣，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮， 等），癌症（白血病，子宫平滑肌肉瘤，前列腺癌，多发性骨髓瘤，恶病质，骨髓纤维化等）等，或其盐。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US11702419B2

公开(公告)日：2023-07-18

申请号：US17201878

申请日：2021-03-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuya Oguro ,  Shigemitsu Matsumoto ,  Takeshi Wakabayashi ,  Norihito Tokunaga ,  Taku Kamei ,  Mitsuhiro Ito ,  Satoshi Mikami ,  Masaki Seto ,  Shinji Morimoto ,  Shinji Nakamura ,  Sachie Takashima ,  Masataka Murakami ,  Masaki Daini ,  Makoto Kamata ,  Minoru Nakamura ,  Yasufumi Wada ,  Hiroyuki Kakei ,  Kazuaki Takami ,  Taisuke Tawaraishi ,  Jumpei Aida ,  Kouichi Iwanaga ,  Satoshi Yamamoto

IPC: C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  C07D471/04 ,  A61P25/00

CPC classification number: C07D487/04 ,  A61K9/2095 ,  A61K9/4833 ,  A61P25/00 ,  C07D471/04

Abstract: The present invention provides a heterocyclic compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and expected to be useful as an agent for the prophylaxis or treatment of major depression, bipolar disorder, migraine, pain, behavioral and psychological symptoms of dementia and the like.
The present invention relates to a compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US11059780B2

公开(公告)日：2021-07-13

申请号：US16491811

申请日：2018-03-07

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masaki Daini ,  Yuhei Miyanohana ,  Satoshi Mikami ,  Yuichi Kajita ,  Masaki Ogino ,  Tatsuki Koike ,  Kohei Takeuchi

IPC: C07D207/12 ,  C07D405/12 ,  C07D403/12 ,  C07D405/14 ,  C07D401/14 ,  C07D417/14 ,  C07D403/14 ,  C07D493/08 ,  C07D487/10 ,  C07D498/10 ,  C07D471/04 ,  C07D413/12 ,  C07D491/107 ,  C07D487/08

Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US10406146B2

公开(公告)日：2019-09-10

申请号：US15754934

申请日：2016-08-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akira Kaieda ,  Naoki Ishii ,  Hiroshi Nara ,  Masato Yoshikawa ,  Masaki Daini

IPC: C07D413/14 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/5377 ,  C07D413/12 ,  C07D417/14 ,  C07D471/04 ,  A61P29/00

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US10308643B2

公开(公告)日：2019-06-04

申请号：US15210965

申请日：2016-07-15

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Akira Kaieda ,  Masashi Toyofuku ,  Masaki Daini ,  Hiroshi Nara ,  Masato Yoshikawa ,  Naoki Ishii ,  Kousuke Hidaka

IPC: C07D413/14 ,  C07D413/04 ,  C07D471/04 ,  C07D491/08 ,  C07D491/107 ,  C07D417/14 ,  C07D498/08

Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US09371320B2

公开(公告)日：2016-06-21

申请号：US14404126

申请日：2013-05-31

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi Nara ,  Masaki Daini ,  Akira Kaieda ,  Toshihiro Imaeda ,  Fumiaki Kikuchi

IPC: C07D401/14 ,  A61K31/437 ,  C07D471/04

CPC classification number: C07D471/04

Abstract: The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof.The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有优异的JAK抑制作用的化合物，其可用作预防或治疗自身免疫性疾病（类风湿性关节炎，牛皮癣，炎性肠病，干燥综合征，白塞病，多发性硬化，系统性红斑狼疮， 等），癌症（白血病，子宫平滑肌肉瘤，前列腺癌，多发性骨髓瘤，恶病质，骨髓纤维化等）等，或其盐。 本发明涉及由下式表示的化合物，其中每个符号如说明书中所定义，或其盐。